At the Heart of Innovation
CardiaTec is applying artificial intelligence on large-scale multiomic data to develop the next generation of cardiovascular disease drug targets
CardiaTec is developing a target discovery platform leveraging AI to make sense of large-scale multiomic cardiovascular data. As opposed to conventional singular omic analysis, CardiaTec’s proprietary platform unravels relationships that span across every level of biology, from gene variation, methylation and expression, to their connection to proteomic and metabolomic functions to best understand disease development.
Driven through new found understanding of disease biology, CardiaTec is exploring Target-Drug interactions to deliver new treatments to patients faster, cheaper and with a reduced risk of failure. CardiaTec’s ultimate goal is to help reduce the global burden caused by cardiovascular diseases, which continues as the world's leading global cause of death, claiming over 17 million lives each year.
Through fully integrated multiomic data aligned with biological modelling, CardiaTec is exploring novel aspects of patient stratification to define patient groups most compatible with our targets & drugs to increase therapeutic outcome. This serves to facilitate the transition into the next paradigm of personalised medicine for cardiovascular diseases, differentiating from the current one-size-fits-all standards of care.
Meet The Founders
CardiaTec was co-founded by a world leading AI academic and ambitious alumni from the University of Cambridge, motivated to change the drug target discovery landscape for cardiovascular diseases.